This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial" [Vaccine 40(19) (2022) 2705–2713]. Issue 25 (31st May 2022)
Record Type:
Journal Article
Title:
Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial" [Vaccine 40(19) (2022) 2705–2713]. Issue 25 (31st May 2022)
Main Title:
Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial" [Vaccine 40(19) (2022) 2705–2713]